Merck, Pfizer sign diabetes drug collaboration

04/30/2013 | Reuters · Genetic Engineering & Biotechnology News

Pfizer and Merck agreed to jointly develop and market the former's investigational type 2 diabetes drug ertugliflozin both as a standalone product and in combination with metformin and Merck's Januvia, or sitagliptin. The deal entitles Pfizer to as much as $60 million in upfront and milestone fees as well as additional payments if certain targets are reached. Merck and Pfizer said they would split potential revenue and some costs on a 60-40 basis.

View Full Article in:

Reuters · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN